Industry Focus

The FDA is investigating Novartis' subsidiary AveXis because AveXis may have manipulated data on Zolgensma, a gene therapy with a sky-high price tag and blockbuster potential. Here's what could happen next. Also, Exact Sciences goes all in on cancer diagnostics. Why the Cologuard-maker is spending $2.7 billion in a push deeper into genetic testing.

Check out more of our content here:

Direct download: 20190814_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EDT